Analysts Set Evolent Health, Inc. (NYSE:EVH) PT at $26.18

Evolent Health, Inc. (NYSE:EVH) has earned a consensus rating of “Buy” from the twelve analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $26.18.

A number of research firms have issued reports on EVH. Barclays reduced their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. JPMorgan Chase & Co. decreased their target price on shares of Evolent Health from $45.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, November 22nd. KeyCorp assumed coverage on Evolent Health in a research report on Friday, October 11th. They set an “overweight” rating and a $35.00 price target on the stock. Citigroup decreased their price objective on Evolent Health from $33.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $20.00 target price on shares of Evolent Health in a research note on Tuesday, November 12th.

Evolent Health Trading Up 2.5 %

Shares of NYSE:EVH opened at $11.25 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health has a 52-week low of $10.53 and a 52-week high of $35.00. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -12.36 and a beta of 1.45. The business has a 50-day moving average price of $14.50 and a 200-day moving average price of $21.50.

Hedge Funds Weigh In On Evolent Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quarry LP acquired a new stake in Evolent Health in the 2nd quarter worth about $32,000. Covestor Ltd lifted its position in shares of Evolent Health by 138.1% in the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after acquiring an additional 1,556 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Evolent Health during the second quarter worth approximately $61,000. Finally, Quest Partners LLC acquired a new position in Evolent Health in the 2nd quarter valued at $87,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.